drugset / Trial / NCT00028769

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00028769

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have metastatic prostate cancer.

Timeline

Start
2001-12
Primary completion
2010-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified Oral
Subject Etoposide Small molecule Oral
Subject Goserelin Other / unclassified Subcutaneous
Subject Leuprolide Other / unclassified Intramuscular
Subject Nilutamide Small molecule Oral
Subject Paclitaxel Small molecule Intravenous
Subject estramustine Other / unclassified Oral
Subject flutamide Small molecule Oral

Indications